Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rita Quintana

Physician Assistant Miami, FL Physician Assistant

NPI 1306228101 CMS profile 10561657

8900 N Kendall Dr, Miami, FL 33101

Open in the dashboard

General payments

$110,450

179 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rita Quintana of Miami, FL is reported in the CMS Open Payments database as having received $110,450 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,871 23
2024 General $1,196 23
2023 General $35,969 52
2022 General $71,067 70
2021 General $347 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rita Quintana
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Rita Quintana were reported at $1,871. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Rita Quintana Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $347 $132 $37–$438 $132
2022 $71,067 $155 $48–$522 $149
2023 $35,969 $167 $52–$557 $160
2024 $1,196 $178 $55–$600 $164
2025 $1,871 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sientra, Inc. $103,160 68 payments
  2. Musculoskeletal Transplant Foundation Inc. $2,341 22 payments
  3. Mentor Worldwide LLC $1,674 48 payments
  4. Allergan Inc. $1,540 11 payments
  5. AbbVie, Inc. $1,043 19 payments
  6. AxoGen $293 2 payments
  7. Integra LifeSciences Corporation $179 3 payments
  8. Stryker Corporation $123 1 payment
  9. Davol Inc. $48 2 payments
  10. KCI USA, Inc $29 2 payments
  11. Other $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $68,228 42 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34,417 20 payments
  3. Food and Beverage $6,594 114 payments
  4. Travel and Lodging $1,211 3 payments
Products named General payments · program years 2021–2025
  1. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $103,160 68 payments
  2. NATRELLE SALINE-FILLED BREAST IMPLANTS $1,400 9 payments
  3. MENTOR MemoryGel Resterilizable Gel Sizer $1,145 31 payments
  4. ARTOURA Breast Tissue Expander $1,119 27 payments
  5. ALLODERM $707 10 payments
  6. AXOGUARD NERVE CAP $293 2 payments
  7. Avance Nerve Graft $293 2 payments
  8. AXOGUARD NERVE PROTECTOR $293 2 payments
  9. AxoGuard Nerve Connector $293 2 payments
  10. Axoguard HA+ Nerve Protector $293 2 payments
  11. Other $1,665 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

213

Median for Physician Assistant: 241

Drug cost

$850

Median for Physician Assistant: $4,110

Branded share of claims

12.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 45 $197
Cyclobenzaprine Hcl Generic 51 $173
Cefadroxil Generic 25 $116
Mupirocin Generic 17 $108
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $97
Doxycycline Hyclate Generic 11 $80
Ondansetron Hcl Generic 37 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$9,748

Medicare's payments for the services billed

Medicare patients

38

Average age 70

Services billed

256

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 68%
Arthritis 47%
Osteoporosis 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record